2 results
8-K
EX-99.2
ANNX
Annexon, Inc.
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
improvement over months to years as nerve Autoantibodies regeneration takes place ~20% unable to walk or dead at 1 year and Infection additional 20
8-K
EX-99.1
ANNX
Annexon, Inc.
4 Mar 24
Regulation FD Disclosure
5:25pm
regeneration takes place ~20% unable to walk or dead at 1 year Additional ~20% continue to experience symptoms Course of GBS Infection Antiganglioside
- Prev
- 1
- Next